1-(Hexadecyloxy)-3-hydroxypropan-2-YL octadecanoate | 84244-35-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: 1-(Hexadecyloxy)-3-hydroxypropan-2-YL octadecanoate
• 英文别名: (1-hexadecoxy-3-hydroxypropan-2-yl) octadecanoate
• CAS: 84244-35-9
• 化学式: C₃₇H₇₄O₄
• 分子量: 583.0
• InChiKey: ALBMTLREXAADKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.5
• 重原子数：
  41
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(Hexadecyloxy)-3-hydroxypropan-2-YL octadecanoate 、 1-anthroylnitrile 、 4-二甲氨基吡啶 生成 [(2S)-3-hexadecoxy-2-octadecanoyloxypropyl] anthracene-1-carboxylate
  参考文献：
  名称：

  RAMESHA, CHAKKODABYLU S.;PICKETT, WALTER C.;KRISHNA, MURTHY D. V., J. CHROMATOGR. BIOMED. APPL., 491,(1989) N, C. 37-48

  摘要：

  DOI：
• 作为产物：
  描述：

  (3-Hexadecoxy-2-octadecanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate 生成 1-(Hexadecyloxy)-3-hydroxypropan-2-YL octadecanoate
  参考文献：
  名称：

  RAMESHA, CHAKKODABYLU S.;PICKETT, WALTER C.;KRISHNA, MURTHY D. V., J. CHROMATOGR. BIOMED. APPL., 491,(1989) N, C. 37-48

  摘要：

  DOI：

文献信息

• PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS
  申请人：Promentis Pharmaceuticals, Inc.

  公开号：US20150344419A1

  公开（公告）日：2015-12-03

  The invention relates to compounds of the following formula: and their pharmaceutically acceptable salts, pharmaceutical compositions containing this compounds, and methods of using this compound for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

  本发明涉及下列式的化合物：以及它们的药学上可接受的盐、含有该化合物的药物组合物，以及使用该化合物治疗各种疾病或病况的方法，包括但不限于涉及中枢神经系统（CNS）的疾病和/或病况，包括精神分裂症、肾上腺白质异形增生症、线粒体疾病（例如 Leigh 综合征、Alpers 病和 MELAS）、亨廷顿病、拔发癖、艾滋病相关神经认知障碍、缺氧缺血性脑病、药物渴求和药物成瘾。
• FOGLIA, T. A.;VAIL, P. D.;IWAMA, T., LIPIDS, 22,(1987) N 5, 362-365
  作者：FOGLIA, T. A.、VAIL, P. D.、IWAMA, T.

  DOI：——

  日期：——
• SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS
  申请人：Promentis Pharmaceuticals, Inc.

  公开号：EP3066089A1

  公开（公告）日：2016-09-14
• METHODS FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE AND/OR LIPODYSTROPHY
  申请人：InteKrin Therapeutics, Inc.

  公开号：US20160263098A1

  公开（公告）日：2016-09-15

  The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT131 and optionally vitamin E or compositions thereof. NAFLDs that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Lipodystrophic syndromes that may be treated with the methods and compositions of the present invention include, but are not limited to, generalized lipodystrophy including congenital generalized lipodystrophy and acquired generalized lipodystrophy and/or partial lipodystrophy, including congenital partial lipodystrophy and acquired partial lipodystrophy, all of which may or may not include hyperlipidemia and/or hyperglycemia and may or may not include NAFLD.
• US5041648A
  申请人：——

  公开号：US5041648A

  公开（公告）日：1991-08-20